# To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

Study · id `cardio:ct-nct01935167` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01935167](<https://clinicaltrials.gov/study/NCT01935167>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01935167

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

## Technical summary

Registry record NCT01935167. Randomized; double masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 158 participants (enrolled count; ClinicalTrials.gov record NCT01935167, source copy `cardio:ctgov-nct01935167-2017-02-17`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01935167, source copy `cardio:ctgov-nct01935167-2017-02-17`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01935167, source copy `cardio:ctgov-nct01935167-2017-02-17`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01935167, source copy `cardio:ctgov-nct01935167-2017-02-17`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01935167, source copy `cardio:ctgov-nct01935167-2017-02-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01935167-2017-02-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
- Condition: Diabetic Nephropathy
- Intervention (Drug): DW1029M 600mg
- Intervention (Drug): DW1029M 1200mg
- Intervention (Drug): Placebo
- Lead sponsor: Dong Wha Pharmaceutical Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 30b28a67cedca1fd6f7fd3c40ab7ecb5ba64e0e0a2e9054b80690d8c4da5e353
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
